In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Kaleidos Pharma Inc.

Latest From Kaleidos Pharma Inc.

Start-Up Previews (1/02)

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, Stem Cell Technologies, features profiles of NeuroNova AB, StemCo Biomedical Inc., StemSource Inc. and StemCo Biomedical Inc. Plus these Selected Start-Ups across Health Care: Fluidigm Corp., MelTec GMBH, NeuroVision Inc. and Psychogenics Inc.

Stem Cell Pharmaceuticals Inc.

Stem Cell Pharmaceuticals has several composition of matter and use patents on members of a family of growth factors that cause resident adult stem cells to proliferate, migrate to a site of injury, and differentiate into the type of cell that's needed. It aims to develop an injectable drug that will enhance a patient's own stem cell-based repair mechanisms, providing a therapy that is much safer and easier to administer than stem cell transplantation, company founders believe.
BioPharmaceutical Regenerative Medicine

Stem Cell Technologies: Entering the Next Generation of Cellular Therapies

With use of embryonic stem cells problematic because of ethical and technical issues, the competitive landscape in cell therapy is being shaped by the adult stem cell opportunity. The firms profiled in this issue are taking a variety of approaches. NeuroNova has shown that neural stem cells transplanted into mouse blastocysts could differentiate into heart, liver, and intestinal cells, and is using its stem cells as a drug discovery tool to identify a broader range of factors affecting cell differentiation in the brain it can potentially turn into drugs. Stem Cell Pharmaceuticals wants to build a franchise around TGF-alpha, which causes adult stem cells to proliferate, induces migration of new cells, and allows their subsequent differentiation into fully functional tissue. StemCo Biomedical has developed a way to measure intracellular activity of aldehyde dehydrogenase, an enzyme highly expressed in stem cells, as a marker for isolating the cells and separating them out. StemSource Inc. has created a stem cell bank for individuals to store their own stem cells, which the company isolates from adipose (fat) tissue, for future use.
BioPharmaceutical Platform Technologies

NeuroNova AB

Sweden's NeuroNova has identified a convenient and accessible source of neural stem cells in the ependymal layer of the brain. The company hopes to use such cells for transplantation therapy in Parkinson's disease and as a platform for drug discovery.
Regenerative Medicine
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Pharmaceuticals
  • Therapeutic Areas
  • Alias(es)
  • Stem Cell Pharmaceuticals Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Kaleidos Pharma Inc.
  • Senior Management
  • Robert M Littauer, CEO & Dir.
    John M Reno, PhD, Pres.
  • Contact Info
  • Kaleidos Pharma Inc.
    Phone: (206) 332-0712
    562 First Ave. S.
    Ste. 100
    Seattle, WA 98104